Changes in stromal tumor infiltrating lymphocytes after treatment with trastuzumab-pertuzumab based regimens in patients with early stage HER2 positive breast cancer

Trial Profile

Changes in stromal tumor infiltrating lymphocytes after treatment with trastuzumab-pertuzumab based regimens in patients with early stage HER2 positive breast cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Carboplatin (Primary) ; Pertuzumab (Primary) ; Taxanes (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Jul 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top